IL17A and psoriatic arthritis: In phase II and III clinical trials, neutralizing monoclonal antibodies against IL-17A (secukinumab and ixekizumab)10, 11, 12 or its receptor IL-17RA (brodalumab)13 are highly efficacious in treating moderate to severe plaque psoriasis and psoriatic arthritis.